Role of CXC group chemokines in lung cancer development and progression
Author:
- 1 April 2017
- journal article
- conference paper
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 9 (S3) , S164-S171
Abstract
Background: Clinical and translational research on lung cancer patients undergoing surgical treatment can provide valuable scientific data and unique opportunity to study tumor microenvironment. CXC chemokines, which are members of a big family of cytokines, are undoubtedly involved in tumor growth regulation and metastasizing pathways. For better understanding of CXC chemokine involvement in the process of carcinogenesis we have studied the cohort of early stage non-small cell lung cancer patients undergoing surgery with curative intent. Our aim was to assess CXC chemokine ligand (CXCL) levels in patient blood samples representing systemic circulation and tumor microenvironment; assess CXC chemokine receptor (CXCR) expression in tumor tissue; and measure tumor infiltrating immune cell subpopulations. Methods: A total of 54 patients with NSCLC had radical lung resection were enrolled in a single center prospective study and were followed-up annually for up to six years. During surgical procedure peripheral and tumor draining blood samples were taken. CXCL1, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11 and CXCL12 levels were determined by ELISA, and chemokine concentration gradient was calculated. Tumor infiltrating immune cells (T helper cells, T cytotoxic cells, macrophages, B cells, plasma cells) and expression of CXCR1, CXCR2, CXCR3 and CXCR4 in tumor tissue were assessed by immunohistochemistry. Results: Statistically significant decrease in chemokine concentration was found for CXCL4 (P=0.002) and CXCL5 (P=0.011), and statistically significant concentration increase was found for CXCL7 (P=0.001) in total cohort. We have found statistically significant CXC chemokine concentration change for majority of chemokines—CXCL1 (P=0.002), CXCL4 (P=0.001), CXCL5 (P=0.013), CXCL7 (P=0.036), CXCL8 (P=0.026), CXCL9 (P=0.034) and CXCL10 (P=0.032) in a group of patients who had good clinical result after surgery with no evidence of relapse, on the other hand patients with cancer recurrence including local and systemic cancer spread did not show any change of chemokine concentration in blood except for CXCL1 (P=0.041). We have also found that chemokine levels and gradients correlate with CXC receptor expression and number of tumor infiltrating immune cell subpopulations Conclusions: Assessment of tumor microcirculation is useful for evaluation of different types of circulating biomarkers and application of our method can be very wide, integrating thoracic surgeons into translational cancer research.Keywords
This publication has 15 references indexed in Scilit:
- Toward understanding and exploiting tumor heterogeneityNature Medicine, 2015
- Development of a serum biomarker panel predicting recurrence in stage I non–small cell lung cancer patientsThe Journal of Thoracic and Cardiovascular Surgery, 2012
- The immune contexture in human tumours: impact on clinical outcomeNature Reviews Cancer, 2012
- The COOH-Terminal Peptide of Platelet Factor-4 Variant (CXCL4L1/PF-4var47-70) Strongly Inhibits Angiogenesis and Suppresses B16 Melanoma Growth In vivoMolecular Cancer Research, 2010
- CXC chemokines play a critical role in liver injury, recovery, and regenerationThe American Journal of Surgery, 2009
- Establishment of a Multi-Analyte Serum Biomarker Panel to Identify Lymph Node Metastases in Non-small Cell Lung CancerJournal of Thoracic Oncology, 2009
- Cancer immunoediting from immune surveillance to immune escapeImmunology, 2007
- Cancer and the chemokine networkNature Reviews Cancer, 2004
- Chemokines: leucocyte recruitment and activation cytokinesThe Lancet, 1997
- The Functional Role of the ELR Motif in CXC Chemokine-mediated AngiogenesisJournal of Biological Chemistry, 1995